166 related articles for article (PubMed ID: 17509077)
1. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis.
Hamuro T; Kido H; Asada Y; Hatakeyama K; Okumura Y; Kunori Y; Kamimura T; Iwanaga S; Kamei S
FEBS J; 2007 Jun; 274(12):3065-77. PubMed ID: 17509077
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut.
Miller HR; Pemberton AD
Immunology; 2002 Apr; 105(4):375-90. PubMed ID: 11985658
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
4. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
Petersen LC; Bjørn SE; Nordfang O
Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
[TBL] [Abstract][Full Text] [Related]
5. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell.
Schechter NM; Irani AM; Sprows JL; Abernethy J; Wintroub B; Schwartz LB
J Immunol; 1990 Oct; 145(8):2652-61. PubMed ID: 2212656
[TBL] [Abstract][Full Text] [Related]
6. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
Ware JH; Wan XS; Rubin H; Schechter NM; Kennedy AR
Arch Biochem Biophys; 1997 Aug; 344(1):133-8. PubMed ID: 9244390
[TBL] [Abstract][Full Text] [Related]
7. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase.
Frank BT; Rossall JC; Caughey GH; Fang KC
J Immunol; 2001 Feb; 166(4):2783-92. PubMed ID: 11160345
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
9. Mast cell tryptase and chymase in chronic leg ulcers: chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors.
Huttunen M; Harvima IT
Br J Dermatol; 2005 Jun; 152(6):1149-60. PubMed ID: 15948975
[TBL] [Abstract][Full Text] [Related]
10. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.
Nguyen SD; Maaninka K; Lappalainen J; Nurmi K; Metso J; Öörni K; Navab M; Fogelman AM; Jauhiainen M; Lee-Rueckert M; Kovanen PT
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):274-84. PubMed ID: 26681753
[TBL] [Abstract][Full Text] [Related]
11. Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions.
Schechter NM; Wang ZM; Blacher RW; Lessin SR; Lazarus GS; Rubin H
J Immunol; 1994 Apr; 152(8):4062-9. PubMed ID: 8144971
[TBL] [Abstract][Full Text] [Related]
12. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Harvima IT
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):908-15. PubMed ID: 17658999
[TBL] [Abstract][Full Text] [Related]
13. Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions.
Harvima IT; Haapanen L; Ackermann L; Naukkarinen A; Harvima RJ; Horsmanheimo M
Acta Derm Venereol; 1999 Mar; 79(2):98-104. PubMed ID: 10228625
[TBL] [Abstract][Full Text] [Related]
14. Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases.
Reimer JM; Enoksson M; Samollow PB; Hellman L
Mol Immunol; 2008 Apr; 45(7):2116-25. PubMed ID: 18022236
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin I conversion by human and rat chymotryptic proteinases.
Wintroub BU; Schechter NB; Lazarus GS; Kaempfer CE; Schwartz LB
J Invest Dermatol; 1984 Nov; 83(5):336-9. PubMed ID: 6092480
[TBL] [Abstract][Full Text] [Related]
16. Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection.
Kaminska R; Harvima IT; Naukkarinen A; Nilsson G; Horsmanheimo M
J Pathol; 1996 Dec; 180(4):434-40. PubMed ID: 9014866
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.
Li A; Wun TC
Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622
[TBL] [Abstract][Full Text] [Related]
18. Purification and identification of two serine class proteinases from dog mast biochemically and immunologically similar to human proteinases tryptase and chymase.
Schechter NM; Slavin D; Fetter RD; Lazarus GS; Fräki JE
Arch Biochem Biophys; 1988 Apr; 262(1):232-44. PubMed ID: 3128177
[TBL] [Abstract][Full Text] [Related]
19. Albumin is a substrate of human chymase. Prediction by combinatorial peptide screening and development of a selective inhibitor based on the albumin cleavage site.
Raymond WW; Ruggles SW; Craik CS; Caughey GH
J Biol Chem; 2003 Sep; 278(36):34517-24. PubMed ID: 12815038
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
